Plural Carboxamide Groups Or Plural C=o Groups Bonded Directly To The Same Nitrogen Patents (Class 514/616)
  • PHARMACEUTICAL COMPOSITION CONTAINING GLUR2-LACKING AMPAR ANTAGONIST FOR PREVENTING OR TREATING PSYCHIATRIC ILLNESSES
    Publication number: 20130046023
    Abstract: A pharmaceutical composition, comprising a GluR2-lacking AMPAR antagonist as an active ingredient, is effective for preventing or treating mental diseases selected from the group consisting of posttraumatic stress disorder (PTSD), drug addiction, and phobia.
    Type: Application
    Filed: October 24, 2012
    Publication date: February 21, 2013
    Applicant: SNU R&DB FOUNDATION
    Inventor: SNU R&DB Foundation
  • INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME
    Publication number: 20130045978
    Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Application
    Filed: June 22, 2012
    Publication date: February 21, 2013
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Vince S. Yeh
  • AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20130040965
    Abstract: The invention provides aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: October 17, 2012
    Publication date: February 14, 2013
    Applicant: THERAVANCE, INC.
    Inventors: Michael R. Leadbetter, Sean G. Trapp, Daniel D. Long, John R. Jacobsen, Sabine Axt
  • COMPOSITIONS OF MODULATORS OF THE WNT/BETA-CATENIN PATHWAY AND BENZAMIDE AND/OR HYDROXAMIC ACID DERIVATIVES TO TREAT BIPOLAR DISORDER
    Publication number: 20130039998
    Abstract: The present invention is directed to a composition comprising a modulator of the Wnt/?-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/?-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.
    Type: Application
    Filed: December 23, 2009
    Publication date: February 14, 2013
    Applicants: UNIVERSITY OF WASHINGTON, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Daniel Fass, Stephen Haggarty, Edward Scolnick, Randall T. Moon, Travis L. Biechele, Nathan D. Camp
  • INFLUENZA VIRUS INHIBITORS THAT DISRUPT NUCLEOPROTEIN TRIMERIZATION
    Publication number: 20130040952
    Abstract: Methods for identifying agents capable of disrupting a salt bridge in an influenza A virus nucleoprotein corresponding to the E339 . . . R416 salt bridge in SEQ ID NO:1, and thus the trimerization of the NP protein; and uses of such agents, e.g., small molecules and peptides, for inhibiting influenza virus replication and treating infection caused by influenza virus.
    Type: Application
    Filed: August 6, 2012
    Publication date: February 14, 2013
    Applicant: Academia Sinica
    Inventors: Chi-Huey Wong, Ming-Daw Tsai, Ying-Ta Wu, Yih-Shyun E. Cheng, Yu-Hou Chen, Yu-Fang Shen
  • Crystalline solid forms of tigecycline and methods of preparing same
    Patent number: 8372995
    Abstract: Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: February 12, 2013
    Assignee: Wyeth LLC
    Inventors: Lalitha Krishnan, Subodh S. Deshmukh, W. James Huang, Mannching Sherry Ku
  • Calixarene-Based Peptide Conformation Mimetics, Methods of Use, and Methods of Making
    Publication number: 20130035394
    Abstract: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.
    Type: Application
    Filed: September 28, 2012
    Publication date: February 7, 2013
    Applicant: Regents of the University of Minnesota
    Inventor: Regents of the University of Minnesota
  • AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS
    Publication number: 20130035346
    Abstract: The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    Type: Application
    Filed: September 27, 2012
    Publication date: February 7, 2013
    Applicant: AstraZeneca AB
    Inventor: AstraZeneca AB
  • ANTIVIRAL COMPOUNDS AND METHODS
    Publication number: 20130035328
    Abstract: The invention relates to compounds having antiviral activity and methods utilizing the compounds to treat viral infections.
    Type: Application
    Filed: July 19, 2012
    Publication date: February 7, 2013
    Inventors: Peter William Gage, Gary Dinneen Ewart, Lauren Elizabeth Wilson, Wayne Best, Anita Premkumar
  • METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH
    Publication number: 20130029901
    Abstract: Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (RT), having an affinity for bone; a Bone Active Portion (RA) for interacting with and affecting bone; and a Linking Portion (RL) connecting the Bone Targeting Portion and the Bone Active Portion.
    Type: Application
    Filed: July 30, 2012
    Publication date: January 31, 2013
    Inventors: William M. PIERCE, JR., K. Grant TAYLOR, Leonard C. WAITE, Kevyn MERTEN
  • ARACHIDONIC ACID ANALOGS AND METHODS FOR ANALGESIC TREATMENT USING SAME
    Publication number: 20130023510
    Abstract: The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of manufacturing the inventive compounds are provided and pharmaceutical formulations, including injectable and oral dosages, are described. Certain analogs are additionally useful as antipyretic compositions and in related fever reducing treatments.
    Type: Application
    Filed: May 25, 2012
    Publication date: January 24, 2013
    Applicant: Cytometix, Inc.
    Inventors: Lane Brostrom, John R. Falck
  • Facially Amphiphilic Polymers and Oligomers and Uses Thereof
    Publication number: 20130023561
    Abstract: The present invention discloses methods of use of facially amphiphilic polymers and oligomers, including pharmaceutical uses of the polymers and oligomers as antimicrobial agents and antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polymers and oligomers and their compositions, including pharmaceutical compositions. The present invention further discloses the design and synthesis of facially amphiphilic polymers and oligomers.
    Type: Application
    Filed: July 26, 2012
    Publication date: January 24, 2013
    Inventors: William F. DeGrado, Gregory N. Tew, Michael L. Klein, Dahui Liu, Jing Yuan, Sungwook Choi
  • COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY
    Publication number: 20130017249
    Abstract: Here described are compounds consisting of the structure (targeting molecule)m-linker-(targeting molecule)n, wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.
    Type: Application
    Filed: June 8, 2012
    Publication date: January 17, 2013
    Inventors: Yoshiro Niitsu, Joseph E. Payne, John A. Gaudette, Zheng Hou, Victor Knopov, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Yasunobu Tanaka, Violetta Akopian
  • Compositions and methods for treating diabetes and neuropsychological dysfunction
    Patent number: 8354452
    Abstract: The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human subjects, particularly adults or children, and is appropriate to treat various neurological disorders.
    Type: Grant
    Filed: August 1, 2007
    Date of Patent: January 15, 2013
    Assignees: Assistance Publique-Hopitaux de Paris, Universite Paris Descartes
    Inventors: Michel Polak, Paul Czernichow
  • Anti-radical agents
    Publication number: 20120328541
    Abstract: Compounds of the formulae and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of the formula wherein G1 is hydrogen; C1-C22alkyl; C1-C22alkylthio; C2-C22alkylthioalkyl; C5-C7cycloalkyl; phenyl; C7-C9-phenylalkyl; or SO3M; G2 is C1-C22alkyl; C5-C7cycloalkyl; phenyl; or C7-C9-phenylalkyl; E is oxyl or hydroxyl; V is —O—; or —NH—; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G3 are as defined in claim 1; G4 and G5 are each independently of the other hydrogen; or C1-C22alkyl; exhibit marked antiinflammatory action.
    Type: Application
    Filed: September 5, 2012
    Publication date: December 27, 2012
    Inventors: Werner Baschong, Oliver Reich, Sébastien Mongiat
  • PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO
    Publication number: 20120329649
    Abstract: This document discloses molecules having the following formula (“Formula One”): and processes associated therewith.
    Type: Application
    Filed: June 21, 2012
    Publication date: December 27, 2012
    Inventors: James E. Hunter, William C. Lo, Gerald B. Watson, Akshay Patny, Gary D. Gustafson, Dan Pernich, William K. Brewster, Debra L. Camper, Beth Lorsbach, Michael R. Loso, Thomas C. Sparks, Hemant Joshi, Adiraj Mandaleswaran, Ramadevi Sanam, Rambabu Gundla, Pravin S. Iyer
  • METHODS OF DISSOLVING BLOOD CLOTS AND THE LIKE
    Publication number: 20120328709
    Abstract: The present invention provides an aqueous composition and its use for dissolving blood clots in vivo or in clinical or research samples in vitro, said composition comprising at least one chaotropic agent, at least one chelating agent that complexes iron if the chaotropic agent does not complex iron and at least one surface-active emulsifier, the composition being buffered near pH 7.4. The process of dissolving the clot with the aqueous composition is advantageous because it is simple, inexpensive, rapid and can be applied in a variety of contexts, including basic research and clinical situations.
    Type: Application
    Filed: June 21, 2012
    Publication date: December 27, 2012
    Applicant: SYNTHETECH PHARMACEUTICALS, LLC
    Inventors: John S. Fisher, Fred Ahari, Christopher Jon Perry, Lucjan J.J. Hronowski
  • Polycationic Compounds And Uses Thereof
    Publication number: 20120322878
    Abstract: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis.
    Type: Application
    Filed: June 21, 2012
    Publication date: December 20, 2012
    Applicant: POLYMEDIX, INC.
    Inventors: Shaker Mousa, Dahui Liu
  • USE OF CI-994 AND DINALINE FOR THE TREATMENT OF MEMORY/COGNITION AND ANXIETY DISORDERS
    Publication number: 20120322879
    Abstract: The invention relates to methods and compositions for promoting cognitive function and/or treating cognitive function disorders and impairments. In particular the methods are accomplished by administering to a subject CI-994 or dinaline or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.
    Type: Application
    Filed: August 27, 2012
    Publication date: December 20, 2012
    Inventors: Li-Huei Tsai, Ji-Song Guan, Stephen J. Haggarty, Edward Holson, Florence Wagner, Johannes Graeff
  • Composition for noxious organisms-controlling agent and method for using the same
    Patent number: 8329733
    Abstract: The present invention relates to a composition for noxious organisms-controlling agent having a synergistic effect and a method for using said composition, which comprises, as active ingredients thereof, one or more compounds selected from the phthalamide derivatives represented by general formula (I) being useful as an insecticide or acaricide and one or more compounds selected from the compounds having insecticidal, acaricidal or nematocidal activity: wherein R1, R2 and R3 may be the same or different and each represent hydrogen atom, C3-C6 cycloalkyl, -A1-Qp, etc., each of X and Y may be the same or different and represents hydrogen atom, halogen atom, etc., n is an integer of 1 to 4, m is an integer of 1 to 5, and each of Z1 and Z2 represents O or S.
    Type: Grant
    Filed: February 6, 2008
    Date of Patent: December 11, 2012
    Assignee: Nihon Nohyaku Co., Ltd.
    Inventors: Kazuyuki Sakata, Masayuki Morimoto, Hiroshi Kodama, Tetsuyosi Nishimatsu
  • CALIXARENE-BASED PEPTIDE CONFORMATION MIMETICS, METHODS OF USE, AND METHODS OF MAKING
    Publication number: 20120309801
    Abstract: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.
    Type: Application
    Filed: April 24, 2012
    Publication date: December 6, 2012
    Applicant: Regents of the University of Minnesota
    Inventors: Kevin H. Mayo, Thomas R. Hoye, Xuemei Chen
  • INSECTICIDAL COMPOUNDS
    Publication number: 20120309812
    Abstract: The present invention relates to certain bisamide derivatives of formula (I), to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests compounds.
    Type: Application
    Filed: February 1, 2011
    Publication date: December 6, 2012
    Applicant: SYNGENTA CROP PROTECTION LLC
    Inventors: Pierre Joseph Marcel Jung, Christopher Richard Ayles Godfrey, Ottmar Franz Hueter, Peter Renold
  • METHODS, KITS AND COMPOSITIONS FOR AMELIORATING ADVERSE EFFECTS ASSOCIATED WITH TRANSFUSION OF AGED RED BLOOD CELLS
    Publication number: 20120294826
    Abstract: The present invention provides, inter alia, methods for ameliorating an adverse effect in a patient caused by an acute transfusion into the patient of a composition containing aged red blood cells using an iron chelator. Apparatuses and kits for ameliorating such adverse effects are also provided.
    Type: Application
    Filed: December 1, 2011
    Publication date: November 22, 2012
    Inventors: Steven L. Spitalnik, Eldad A. Hod, Gary M. Brittenham
  • INSECTICIDAL COMPOUNDS
    Publication number: 20120295907
    Abstract: The present invention relates to bis-amide derivatives of formula (I), to processes and intermediates for preparing them, to methods of using them to control insect, acarine, nematode and mollusc pests, and to insecticidal, acaricidal, nematicidal and molluscicidal compositions comprising them.
    Type: Application
    Filed: April 14, 2010
    Publication date: November 22, 2012
    Applicant: SYNGENTA CROP PROTECTION, LLC
    Inventors: Peter Maienfisch, Christopher Richard Ayles Godfrey, Pierre Joseph Marcel Jung, Ottmar Franz Hueter, Peter Renold
  • Aminotetralin compounds as mu opioid receptor antagonists
    Patent number: 8314128
    Abstract: The invention provides aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: November 20, 2012
    Assignee: Theravance, Inc.
    Inventors: Michael R. Leadbetter, Sean G. Trapp, Daniel D. Long, John R. Jacobsen, Sabine Axt
  • Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
    Publication number: 20120289512
    Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Application
    Filed: May 10, 2012
    Publication date: November 15, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jeffrey J. Rohde, Qi Shuai, James T. Link, Jyoti R. Patel, Jurgen Dinges, Bryan K. Sorensen, Hong Yong, Vince S. Yeh, Ravi Kurukulasuriya
  • SARMs and method of use thereof
    Patent number: 8309603
    Abstract: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: November 13, 2012
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Jeff Kearbey
  • CATHEPSIN INHIBITORS FOR THE TREATMENT OF BONE CANCER AND BONE CANCER PAIN
    Publication number: 20120282267
    Abstract: The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.
    Type: Application
    Filed: May 2, 2012
    Publication date: November 8, 2012
    Applicant: ViroBay, Inc.
    Inventor: Robert Booth
  • CYSTEINE PROTEASE INHIBITORS
    Publication number: 20120283305
    Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4 is C1-C6alkyl, C1-C6haloalkyl, C1-C6alkylamino or C1-C6dialkylamino; for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.
    Type: Application
    Filed: December 10, 2010
    Publication date: November 8, 2012
    Applicant: Medivir UK LTD
    Inventors: Susana Ayesa, Peter Carlqvist, Karolina Ersmark, Urszula Grabowska, Ellen Hewitt, Daniel Jönsson, Pia Kahnberg, Björn Klasson, Peter Lind, Lourdes Odén, Kevin Parkes, Daniel Wiktelius
  • FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES
    Publication number: 20120277305
    Abstract: The invention relates to fatty acid guanidine or salicylate guanidine derivatives; compositions comprising an effective amount of a fatty acid guanidine or salicylate guanidine derivative; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid guanidine or salicylate guanidine derivative.
    Type: Application
    Filed: April 27, 2012
    Publication date: November 1, 2012
    Applicant: CATABASIS PHARMACEUTICALS, INC.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu, Amal Ting
  • PHOTOSENSITIZERS FOR TARGETED PHOTODYNAMIC THERAPY
    Publication number: 20120264802
    Abstract: The present invention relates to photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof.
    Type: Application
    Filed: May 31, 2012
    Publication date: October 18, 2012
    Applicants: Lynntech, Inc., The General Hospital Corporation
    Inventors: Tim Wharton, Hariprasad Gali, Michael R. Hamblin
  • Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
    Patent number: 8288368
    Abstract: (R)-2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use in the inhibition of the chemotaxis of neutrophils and monocytes induced by the C5a fraction of the complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of PMN leukocytes.
    Type: Grant
    Filed: February 25, 2002
    Date of Patent: October 16, 2012
    Assignee: Dompé Pha.R.Ma S.p.A.
    Inventors: Marcello Allegretti, Riccardo Bertini, Valerio Berdini, Cinzia Bizzarri, Maria Candida Cesta, Vito Di Cioccio, Gianfranco Caselli, Fracesco Colotta, Carmelo Gandolfi, Janete Peloia Barroso Gandolfi, legal representative, Giulio Agostino Gandolfi, legal representative, Maria Carla Gandolfi, legal representative, Arrigo Aldo Gandolfi, legal representative
  • Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
    Patent number: 8288442
    Abstract: A method for the treatment or prevention of pain and/or a headache disorder using a derivative of a valproic acid amide or a 2-valproenic acid amide, as well as pharmaceutical compositions comprising these derivatives or compounds.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: October 16, 2012
    Assignee: Yissum Research Development Company of The Hebrew University of Jerusalem
    Inventors: Mitchell Shirvan, Meir Bialer
  • NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE
    Publication number: 20120258960
    Abstract: The invention relates to compounds of the general formula (1) or the acid addition salts thereof with organic and/or inorganic acids; as well as to the use of the compounds of the general formula (1) in medicine.
    Type: Application
    Filed: August 26, 2010
    Publication date: October 11, 2012
    Applicant: IMTM GMBH
    Inventors: Siegfried Ansorge, Ute Bank, Karsten Nordhoff, Peter Roehnert, Sofia Stefin, Frank Striggow, Michael Taeger
  • Methods for treatment of parkinson's disease
    Patent number: 8283380
    Abstract: New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: October 9, 2012
    Assignee: Newron Pharmaceuticals S.p.A.
    Inventors: Ruggero Fariello, Carlo Cattaneo, Patricia Salvati, Luca Benatti
  • METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION
    Publication number: 20120252792
    Abstract: The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.
    Type: Application
    Filed: September 17, 2010
    Publication date: October 4, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Richard Neubig, Chris Evelyn, Jenny Ryu, Scott Larsen, Jessica Bell
  • METHOD OF REMOVING E. COLI BACTERIA FROM AN AQUEOUS SOLUTION
    Publication number: 20120252899
    Abstract: The method of removing Escherichia coli (E. coli) bacteria from an aqueous solution includes the step of mixing multi-walled carbon nanotubes functionalized with a dodecylamine group (C12H27N) into an aqueous solution containing E. coli bacteria. The multi-walled carbon nanotubes functionalized with a dodecylamine group have an antimicrobial effect against the E. coli bacteria. The multi-walled carbon nanotubes may be mixed into the aqueous solution at a concentration of between approximately 0.2 g and 0.007 g of multi-walled carbon nanotubes functionalized with a dodecylamine group per 100 ml of the aqueous solution.
    Type: Application
    Filed: March 29, 2011
    Publication date: October 4, 2012
    Applicant: KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS
    Inventors: MUATAZ ALI ATIEH, AMJAD BAJES KHALIL, TAHAR LAOUI, SAMER MOHAMMED AL-HAKAMI
  • FATTY ACID ACETYLATED SALICYLATES AND THEIR USES
    Publication number: 20120238586
    Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
    Type: Application
    Filed: March 22, 2012
    Publication date: September 20, 2012
    Applicant: CATABASIS PHARMACEUTICALS, INC.
    Inventors: Jill C. MILNE, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
  • FATTY ACID ACETYLATED SALICYLATES AND THEIR USES
    Publication number: 20120238585
    Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
    Type: Application
    Filed: March 22, 2012
    Publication date: September 20, 2012
    Applicant: CATABASIS PHARMACEUTICALS, INC.
    Inventors: Jill C. MILNE, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
  • Entry inhibitors of the HIV virus
    Patent number: 8268885
    Abstract: The present invention relates to small molecules as entry inhibitors of the HIV virus, processes for their preparation as well as pharmaceutical compositions, their use as medicines, and diagnostic kits comprising them. The present invention also concerns combinations of the present entry inhibitors with other anti-retroviral agents. It further relates to their use in assays as reference compounds or as reagents. The compounds of the present invention are useful for preventing or treating infection by HIV and for treating AIDS.
    Type: Grant
    Filed: September 10, 2004
    Date of Patent: September 18, 2012
    Assignee: Janssen R&D Ireland
    Inventors: Koenraad Lodewijk August Van Acker, Piet Tom Bert Paul Wigerinck, Lieve Emma Jan Michiels, Abdellah Tahri
  • NOVEL COLCHICINE DERIVATIVES, METHODS AND USES THEREOF
    Publication number: 20120225912
    Abstract: The invention relates to colchicine derivatives, methods and uses thereof for treatment of cancer.
    Type: Application
    Filed: July 30, 2010
    Publication date: September 6, 2012
    Inventors: Jack Tuszynski, Jonathan Y. Mane, John Torin Huzil, Boguslaw Tomanek, Dorota Bartusik
  • SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY
    Publication number: 20120225871
    Abstract: Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.
    Type: Application
    Filed: June 8, 2010
    Publication date: September 6, 2012
    Applicant: Dendreon Corporation
    Inventors: Ofir Moreno, Sateesh Natarajan, David F. Duncan
  • AMIDE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS INSECTICIDE
    Publication number: 20120225891
    Abstract: A compound represented by Formula (1): The compound can be used as insecticides.
    Type: Application
    Filed: March 22, 2012
    Publication date: September 6, 2012
    Applicant: MITSUI CHEMICALS, INC.
    Inventors: Kei Yoshida, Takeo Wakita, Hiroyuki Katsuta, Akiyoshi Kai, Yutaka Chiba, Kiyoshi Takahashi, Hiroko Kato, Nobuyuki Kawahara, Michikazu Nomura, Hidenori Daido, Junji Maki, Shinichi Banba
  • Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same
    Publication number: 20120220593
    Abstract: A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group ?; and X is, for example, a hydroxyl group or a C1-C6 alkoxy group].
    Type: Application
    Filed: February 24, 2012
    Publication date: August 30, 2012
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Kazumasa Aoki, Koji Suda, Toshio Kaneko, Tomio Kimura
  • SOLID FORMS OF ALISKIREN HEMIFUMARATE AND PROCESSES FOR PREPARATION THEREOF
    Publication number: 20120220663
    Abstract: The present invention provides polymorphic forms of aliskiren hemifumarate, and processes for preparation thereof and for the preparation of the amorphous form of aliskiren hemifumarate. The present invention also provides pharmaceutical compositions comprising the aliskiren hemifumarate crystalline forms T1, T3 or T4, T5, T6, T7, T8 and at least one pharmaceutically acceptable excipient, and the use of these pharmaceutical compositions in the treatment of hypertension.
    Type: Application
    Filed: September 2, 2010
    Publication date: August 30, 2012
    Applicants: TEVA PHARMACEUTICALS USA, INC., TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Marina Etinger, Rinat Moshkovits Kaptsan, Ariel Mittelman
  • MODIFIED RELEASE FORMULATION OF LACOSAMIDE
    Publication number: 20120219631
    Abstract: The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.
    Type: Application
    Filed: November 3, 2010
    Publication date: August 30, 2012
    Applicant: LUPIN LIMITED
    Inventors: Shirishkumar Kulkarni, Satish Kumar Dalal, Harshal Jahagirdar, Kishore Kumar Konda
  • Aminobenzamide Derivatives as Useful Agents for Controlling Animal Parasites
    Publication number: 20120214851
    Abstract: The invention relates to a composition comprising at least one aminobenzamide compound or a salt thereof for controlling animal parasites, veterinary pharmaceutical compositions comprising at least one aminobenzamide of formula (I) for preventing infection with diseases transmitted through parasites, its use for the preparation of a veterinary pharmaceutical for controlling animal parasites, and a method for preventing infection with diseases transmitted through parasites.
    Type: Application
    Filed: April 26, 2012
    Publication date: August 23, 2012
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Ulrich GÖRGENS, Akihiki YANAGI, Kazue YANAGI, Keisuke YANAGI, Kasumi YANAGI, Katsuaki WADA, Tetsuya MURATA, Yukiyoshi WATANABE, Jun MIHARA, Koichi ARAKI
  • Acyl Guanidine Derivatives Modulating The Hedgehog Protein Signaling Pathway
    Publication number: 20120196865
    Abstract: The present invention relates to acyl guanidine derivatives modulating the hedgehog protein signaling pathway to be used as drugs, in particular for treating diseases involving a tissue dysfunction associated with a deregulation of the hedgehog protein signaling pathway, as well as to pharmaceutical compositions containing same. The present invention also relates to novel acyl guanidine derivatives as such.
    Type: Application
    Filed: July 19, 2010
    Publication date: August 2, 2012
    Applicants: UNIVERSITE DE STRASBOURG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Martial Ruat, Hélène Faure, Elisabeth Traiffort, Hermine Roudaut, André Mann, Angèle Schoenfelder, Maurizio Taddei, Fabrizio Manetti, Antonio Solinas
  • THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
    Publication number: 20120196824
    Abstract: The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.
    Type: Application
    Filed: October 8, 2010
    Publication date: August 2, 2012
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Akira Nakao, Hiroko Suzuki, Ryo Tatsumi, Tomofumi Setsuta, Maki Seki, Hiroshi Iwasaki, Minoru Tanaka
  • BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS
    Publication number: 20120196916
    Abstract: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.
    Type: Application
    Filed: April 9, 2012
    Publication date: August 2, 2012
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty